Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 In Vivo by Michelfelder, Stefan et al.
Peptide Ligands Incorporated into the Threefold Spike
Capsid Domain to Re-Direct Gene Transduction of AAV8
and AAV9 In Vivo
Stefan Michelfelder1, Karl Varadi3, Christina Raupp4, Agnes Hunger1, Jakob Ko¨rbelin1, Christiane
Pahrmann2, Sonja Schrepfer2, Oliver J. Mu¨ller3, Ju¨rgen A. Kleinschmidt4, Martin Trepel1*
1Department of Oncology and Hematology, Hubertus Wald Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2 Transplant and Stem
Cell Immunobiology Lab, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 3 Internal Medicine III, University Medical Center Heidelberg, Im
Neuenheimer Feld 10, Heidelberg, Germany, 4Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, Heidelberg, Germany
Abstract
Efficiency and specificity of viral vectors are vital issues in gene therapy. Insertion of peptide ligands into the adeno-
associated viral (AAV) capsid at receptor binding sites can re-target AAV2-derived vectors to alternative cell types. Also, the
use of serotypes AAV8 and -9 is more efficient than AAV2 for gene transfer to certain tissues in vivo. Consequently, re-
targeting of these serotypes by ligand insertion could be a promising approach but has not been explored so far. Here, we
generated AAV8 and -9 vectors displaying peptides in the threefold spike capsid domain. These peptides had been selected
from peptide libraries displayed on capsids of AAV serotype 2 to optimize systemic gene delivery to murine lung tissue and
to breast cancer tissue in PymT transgenic mice (PymT). Such peptide insertions at position 590 of the AAV8 capsid and
position 589 of the AAV9 capsid changed the transduction properties of both serotypes. However, both peptides inserted in
AAV8 did not result in the same changes of tissue tropism as they did in AAV2. While the AAV2 peptides selected on murine
lung tissue did not alter tropism of serotypes 8 and -9, insertion of the AAV2-derived peptide selected on breast cancer
tissue augmented tumor gene delivery in both serotypes. Further, this peptide mediated a strong but unspecific in vivo
gene transfer for AAV8 and abrogated transduction of various control tissues for AAV9. Our findings indicate that peptide
insertion into defined sites of AAV8 and -9 capsids can change and improve their efficiency and specificity compared to
their wild type variants and to AAV2, making these insertion sites attractive for the generation of novel targeted vectors in
these serotypes.
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Introduction
Systemic vector administration would be the most appropriate
delivery pathway in many, if not most, potential gene therapy
applications, especially in disseminated disease when local
administration is not feasible. Adeno-associated viruses (AAV)
provide a well established platform for the development of safe and
efficient vector systems [1,2,3,4]. Among the various serotypes,
AAV8 and -9 have features making them particularly attractive as
vectors. Upon systemic administration, AAV8 and -9 cross
vascular endothelial barriers more efficiently than other serotypes,
resulting in efficient gene delivery to hepatocytes, cardiac and
skeletal muscle cells [5,6,7]. AAV9 can even efficiently deliver
genes to various cell-types of the central nervous system [8] and
has the unique property to cross the blood-brain barrier (BBB)
[9,10]. Another advantage over AAV2 vectors is an only moderate
sero-prevalence of antibodies against AAV8 and -9 among the
human population, potentially facilitating the immune escape of
vectors in vivo [11]. All of these properties may contribute to the
fact that AAV8 and -9 deliver genes to a wider range of tissues and
with higher efficiency compared to other AAV serotypes
[6,7,12,13]. This may, however, also account for some major
drawbacks regarding their utility as therapeutic vectors, because
their broad and efficient tissue tropism may result in un-intended
transduction of various tissues. In addition, the inefficient
transduction of certain tissues may also limit their utility for
distinct potential applications. Therefore, the development of cell-
or tissue-targeted AAV8 and -9 vector capsids appears to be an
important goal.
Receptor-directed targeting of AAV has been achieved most
often by genetic insertions into the cap gene of AAV2, resulting in
display of small peptide ligands (up to 34 amino acids) [4,14].
Suitable peptides binding to cellular receptors can be identified by
screening combinatorial peptide libraries displayed on bacterio-
phage [15,16,17,18,19] which subsequently may be introduced
into the viral capsid [20,21,22,23,24,25,26,27]. Alternatively,
AAV peptide libraries in which random peptides are displayed
within the viral capsid can be used for this purpose [28,29,30].
Screening random AAV peptide libraries has several advantages
over insertion of ligands selected by phage display since the
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selection of the suitable peptide takes into account the structural
constraints of the viral capsid and therefore will reveal only capsid
variants that are compatible with virus attachment and post-entry
processing within the target cell. Such AAV peptide libraries have
been used to target a variety of cell types in vitro
[20,21,22,28,29,30,31,32]. Recently, this challenging approach
has been translated into in vivo applications, yielding capsid
variants with improved tropism towards murine lung [32], breast
cancer [32], or cardiac tissue [33].
The capsid region surrounding amino acid R588 (VP
numbering) has been used most often for the incorporation of
peptide ligands into AAV2 for several reasons. Such peptide
insertions are compatible with capsid assembly. Furthermore, the
targeting peptide is presented 60 times near the top of protruding
capsid domains within the threefold spike region, facilitating the
interaction with potential cell surface structures [20,32]. Since
AAV2 attachment to its primary cellular receptor heparan sulfate
proteoglycan (HSPG) is mediated by a cluster of basic amino acid
residues within this capsid region surrounding position 588 [34],
manipulating this region including insertion of peptides results in
abrogation of HSPG binding. In vivo, this results in de-targeting
AAV2 from its main target tissue, the liver [32,33,35]. Further-
more, such modifications may mediate escape from neutralizing
antibodies against the AAV2 capsid [36].
The aim of this study was to re-target AAV8 and -9-based
vectors to alternative tissues in vivo by genetic insertion of peptide
ligands into domains putatively involved in receptor binding. The
topology of AAV8 is based on the same structure previously
described for AAV2 and comprises a characteristic eight stranded
ß-barrel with large interstrand loop domains. Significant differ-
ences between AAV8 and -2 are located in protruding surface
residues adjacent to the three axes of symmetry [37]. Capsid
swapping analysis between AAV2 and -8 identified interstrand
loop domains exposed within the threefold proximal peak (mainly
loop IV domain, subloops 1–4) as the critical structural
determinant for AAV8 transduction [38]. The 37/67-kDa laminin
receptor (lamR) has been identified as a cellular receptor for
AAV8 and -9 and residues 491–547 within the protrusions that
surround the threefold axis as well as 593–623 near this axis [39]
may be the respective capsid binding sites for AAV8. Koerber et al.
inserted a hexahistidine (His6) at position 590 that allowed
purification of AAV8 vectors via immobilized metal affinity
chromatography (IMAC). However, in vivo gene transduction of
such mutant AAV8 capsids was unchanged compared to its wild
type origin [40].
Here we used the site adjacent to the threefold-spike domain in
the capsid of AAV serotypes 8 and -9 and explored the effects of
inserting peptides selected by screening AAV2 peptide libraries in
putatively equivalent sites of AAV8 and -9. We show that
introduction of such peptides can alter the wild type tropism of
AAV8 and -9 and enhance gene delivery to certain tissues, some
being and some not being the originally intended target. These
effects were serotype-dependent. Re-direction of AAV8 and -9
vectors by tumor-homing peptides selected from AAV2 libraries
improved gene transfer efficiency to breast cancer tissue even
beyond the level of the equivalent re-directed AAV2 variant,
while, particularly in AAV9, gene expression in various control
tissues was diminished. Our findings demonstrate that re-direction
of the tropism of AAV serotypes other than AAV2 can change and
partially improve efficiency and specificity of the vectors even
when the peptides used therefore were initially selected from
AAV2 libraries. In addition, the tumor-targeted AAV9 vector
presented here may be used in pre-clinical studies to improve
breast cancer transduction in vivo.
Materials and Methods
Plasmids
To generate an AAV8 backbone plasmid with a peptide
insertion site, SfiI binding sites had to be inserted into the AAV8
cap gene of p5E18-VD2/8 [41]. The SfiI restriction sites within
the sequence of AAV8 were established by synthesizing a 743 bp
AAV8 cap gene segment (Geneart, Regensburg, Germany). The
restriction enzymes XcmI and Eco47III were used to insert the
sequence containing the SfiI sites into p5E18-VD2/8 backbone
(kindly provided by J. Wilson, University of Pennsylvania,
Philadelphia, USA), resulting in p5E18-VD2/8-SfiI.
For generation of the AAV9 plasmid suitable for oligonucleotide
insertion, a 975 bp-fragment of the AAV9 cap ORF containing
two SfiI restriction sites was synthesized (Geneart, Regensburg,
Germany). The two SfiI sites were separated by two adenines to
allow for directed cloning of oligonucleotides directly downstream
of the trinucleotide encoding amino acid position 589 into the cap
gene of AAV9. The analogous AAV9 wild type fragment within
p5E18-VD2/9 [41] (kindly provided by J. Wilson, University of
Pennsylvania, Philadelphia, USA) was replaced with the SfiI-
modified version by BsiWI/XcmI-excision and termed p5E18-
VD2/9-SfiI1759. The oligonucleotides encoding the peptides
VRRPRFW, ESGLSQS, PRSTSDP were amplified from
pMTpXX2-187 plasmids [31], digested by BglI and cloned into
p5E18-VD2/9-SfiI1759 or p5E18-VD2/8-SfiI.
Cell culture, vector production and titering
Human embryonic kidney (HEK) 293T cells (kindly provided
by David Baltimore, California, Institute of Technology, Pasa-
dena, CA) were grown in Dulbecco’s Modified Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA) supplemented with 1%
penicillin/streptomycin solution (Invitrogen) and 10% fetal calf
serum (Biochrom, Berlin, Germany). Recombinant AAV (rAAV)
vectors were produced by Polyfect transfection (Qiagen) cells of
plasmid DNA into HEK 293T (see below). Four days after
transfection, cells were harvested, lysed and vectors were purified
by iodixanol density gradient ultracentrifugation and stored at
280uC. For quantification of vector stocks, genomic titers were
determined by quantitative real-time PCR using the LightCycler
system (Roche Diagnostics, Mannheim, Germany), as described
previously [42]. For transfections, we used pXX6 as adenoviral-
helper plasmid [43], the luciferase-reporter gene pUF2-CMV-luc
[28], and a plasmid encoding the AAV capsid of interest. Plasmids
encoding the respective AAV capsid mutants and wild type
controls were pXX2 [43], and modified pXX2-187 for AAV2
displaying peptides [31], p5E18-VD2/8 and p5E18-VD2/8-SfiI
for AAV8 and p5E18-VD2/9 and modified p5E18-VD2/9–
SfiI1759 for AAV9, as described above.
Animals and detection of luciferase transgene expression
and vector distribution in vivo
Polyoma middle T transgenic mice (strain FVB/N-
TgN(MMTVPyVT)634-Mul) were purchased from Jackson Lab-
oratory (Bar Harbor, ME). Genotyping and tumor staging was
performed as described previously [32]. All experiments involving
animals were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996) and the German Animal Protection Code. The protocol was
approved by the responsible local authority (‘‘Amt fu¨r Gesundheit
und Verbraucherschutz, Hansestadt Hamburg’’, permission
number 42-09). All experiments were performed under deep
anesthesia as described below, and all efforts were made to
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minimize suffering. For the analysis of luciferase gene transduc-
tion, 8–12 weeks-old female animals were anesthetized by
intraperitoneal injection of 100 mg/kg body weight 10% ketamine
hydrochloride (115.34 mg/ml; Essex, Munich, Germany) and
5 mg/kg body weight 2% xylazine hydrochloride (23.32 mg/ml;
Bayer, Leverkusen, Germany). AAV vectors were injected
intravenously into the tail vein at a dose of 261010 vector
genomes (vg) per mouse in a total volume of 200 ml phosphate-
buffered saline (n = 3 animals per injected AAV clone). At days 14
and 28, mice were anesthetized with 2% isoflurane and oxygen.
Luciferase expression was analysed using a Xenogen IVIS200
imaging system (Caliper Lifesciences) after intraperitoneal injec-
tion of 100 ml luciferin substrate (150 mg/kg, Xenogen). Repre-
sentative in vivo bioluminescence transgene expression images were
taken when luminescence in relative light units (photons/sec/cm2)
reached the highest intensity. Subsequently, the tissues were
removed, snap frozen in liquid nitrogen, and stored at 280uC.
Homogenization was done in reporter lysis buffer (RLB, Promega,
Madison, WI) followed by determination of the luciferase reporter
gene activity in a luminometer (Mithras LB 940, Berthold
Technologies, Bad Wildbad, Germany) using Promega’s luciferase
assay according to the manufacturer’s instructions. Values were
normalized to protein levels in each sample determined by the
Roti Nanoquant Protein assay (Roth, Karlsruhe, Germany). For
quantification of vector genome copy number in various tissues,
total tissue DNA was extracted using the DNeasy tissue kit
(Qiagen) and quantified using a spectral photometer Nanodrop
ND-2000C (Peqlab, Erlangen, Germany). Analysis of AAV vector
DNA in tissues was performed using CMV-specific primers by
quantitative real-time PCR as described above, using 100 ng of
template DNA.
Statistics
All data were expressed as mean6 SEM. Statistical analysis was
performed using the GraphPad Prism program 3.0 (GraphPad
Software, San Diego, CA). Data were analyzed by an unpaired
students-t test. p values,0.05 were considered significant.
Results
Generation of AAV8 and -9 vectors displaying peptides in
capsid domains forming exposed spikes on the capsid
surface
To develop targeted AAV vectors on the basis of serotypes 8
and 9, we identified potential capsid regions amenable for the
insertion of peptides that may re-direct the natural viral tropism.
Since AAV2, -8, and -9 proteins share about 83% of their capsid
amino acid sequences [37,44], we reasoned that sequence
alignment would identify domains potentially mediating the
differential tropism of these three serotypes. Comparison of the
threefold spike regions of the AAV2 VP3 subunit comprising the
HSPG binding domain in AAV2 with corresponding VP
sequences of serotypes 8 and 9 revealed highly conserved regions
(R484/R488), or regions that differ by one amino acid (K532)
without affecting the net charge. However, a strong variability in
capsid regions surrounding R585/R588 suggested that this
domain could contribute to the tropism of these serotypes
(Figure 1A–B). To generate backbone plasmids for the insertion
of oligonucleotides coding for potential targeting peptides, we
modified the wild type AAV8 capsid sequence from QQQN590-
TAPQ to QGQR590-G-Insert-AQAAQ by in vitro gene synthesis
and the wild type AAV9 capsid sequence from AQAQ590-
AQTTGW to GQA589-G-Insert-AQAATGW by in vitro synthesis
of a part of the cap gene (Figure 1C). The resulting two insertion-
backbone plasmids each contained two SfiI restriction sites,
separated by a stuffer allowing the directed insertion of
oligonucleotides encoding a potential targeting peptide. To
investigate whether the insertion of peptides can alter the tropism
of AAV8 and AAV9-derived vectors, we engineered a set of vector
variants displaying peptides selected from AAV2 peptide libraries
[32]. We produced recombinant AAV2, -8, and -9 vectors
displaying the peptides VRRPRFW (random control), PRSTSDP
(selected for lung transduction), and ESGLSQS (selected for breast
and breast tumor tissue transduction) (Figure 1C). Structural
modeling of position R590 in AAV8 vectors indicated that the
peptide is positioned within the threefold spike region, similar to
the peptides inserted at position R588 within the AAV2 capsid
(Figure 1D–E). Genomic titers of all capsid variants ranged
between 861010 to 761011 vg/ml (Table 1). These data suggest
that peptide insertions in these capsid domains do not impair
genome packaging and capsid assembly.
Insertion of targeting peptides changes the tropism of
AAV8 and AAV9 vectors in vivo
To investigate the in vivo tropism of the vector variants described
above, we analyzed luciferase activity in FVB wild type mice 28
days after low vector dose tail vein injections (261010 vg/animal)
by bioluminescence imaging (Figure 2). The insertion of a control
peptide (VRRPRFW) into the capsid of AAV2, -8 and -9 resulted
in transduction-deficient vectors. Insertion of a peptide ligand used
to augment gene transfer of AAV2 in murine lung, liver and
cardiac tissue (PRSTSDP) slightly decreased transgene expression
of AAV8 in the skeletal muscle. For AAV9, the peptide did not
markedly alter the tropism (Figure 2). As expected, insertion of
ESGLSQS into AAV2 capsids resulted in transduction of the
mammary tissue, while the transgene-mediated liver luminescence
disappeared. Introduced into the AAV9 capsid, the ESGLSQS
peptide de-targeted expression mainly from the liver, adopting a
tropism similar to AAV2-ESGLSQS.
We additionally determined the luciferase activity from crude
tissue lysates. Consistent with the in vivo imaging results, control
vectors displaying a randomly chosen peptide (VRRPRFW) did
not mediate gene expression above background in all serotypes
(Figure 3). As expected, insertion of the lung-directed peptide
PRSTSDP significantly enhanced AAV2-mediated transduction
not only of the lung, but also of heart and liver (Figure 3A). For
heart transduction, AAV2 PRSTSDP was even more efficient than
the most efficient AAV serotype for cardiac transduction, AAV9
(AAV2-PRSTSDP: 4.66106 RLU/mg protein vs. AAV9 wild
type: 1.66106 RLU/mg protein; Figure 3A+C). When introduced
into AAV8, PRSTSDP lead to a slight but not significant decrease
in heart transduction compared to wild type AAV8, while
insertion of PRSTSDP had no influence on AAV9 transduction
(Figure 3B+C). Even though selected for optimized lung
transduction, AAV2-PRSTSDP was the most efficient vector for
lung transduction in the three-fold comparison. Insertion of the
ESGLSQS peptide into AAV8 significantly improved gene
delivery to the lung (3.42-fold), kidney (9.88-fold), brain (9.08-
fold), and particularly to the heart (12.15-fold), which was even
more efficient than wild type AAV9 (AAV8-ESGLSQS 2.46106
RLU/mg protein). In contrast, insertion of ESGLSQS into AAV9
capsids significantly decreased AAV9 gene transfer to almost all
control tissues including the liver, the heart, and the skeletal
muscle. These findings were supported by biodistribution analysis
of vector genome copy numbers by quantitative real-time PCR
(Figure 4). For AAV2-PRSTSDP, a high copy number was
recovered in the liver (Figure 4A), in the cardiac muscle
(Figure 4B). In the comparison, the highest copy number was
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Figure 1. Design of novel peptide insertion sites in capsid regions adjacent to the threefold-spike in serotypes AAV8 and AAV9. A:
Sequence alignment of surface exposed capsid domains encoded by the cap gene of the AAV serotypes 2, 8, and 9. Parts of the heparin binding
domain 484-RQQR-487 and the integrin binding motif 511-NGR-513 are strongly conserved among the three serotypes. While AAV8 and -9 both
contain an R at position 532, marked differences in the sequences are apparent at positions 585–588. Domains highlighted in B are tagged by colored
rectangles. Alignment of the serotype sequences was carried out using BioEdit Sequence Alignment Editor Software. B: Capsid domains of AAV2
known to be involved in receptor binding are highlighted in blue (R484; R487), yellow (511-NGR-513), green (K532), and red (R585; R588). Surface
rendering and mapping of the threefold-spike region was performed using PyMOL with the crystal structure of AAV2 supplied as template (PDB ID:
1lp3 [50]). C: Design of AAV8 and -9 constructs for the incorporation of oligonucleotides encoding targeting peptides into the cap gene. The amino
Re-Direction of Tropism of AAV8 and 9 In Vivo
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23101
recovered in the lung of mice injected with AAV2-PRSTSDP
(Figure 4C). For AAV8-ESGLSQS, a higher amount of vector
DNA was detected within cardiac and lung tissue compared to
AAV8 wild type capsids (Figure 4B, C), while inconsistently to the
data we obtained by expression analysis, the highest copy number
we recovered in the cardiac muscle was from AAV9 (Figure 4B).
The amount of vector DNA copies in mice injected with AAV9-
ESGLSQS were about ,21-fold lower in the liver and about ,6-
fold (for AAV9) lower in the cardiac muscle compared to AAV9
wild type (Figure 4A, B), confirming the de-targeting in these
tissues mediated by the peptide selected on breast tumor tissue.
Insertion of breast cancer targeting peptide ligand re-
directs gene transfer of AAV8 and AAV9 to polyoma
middle T-induced breast cancer tissue
Since the primary target the ESGLSQS peptide was selected for
was breast cancer tissue, gene transfer of ESGLSQS vectors of all
three serotypes was analyzed in polyoma middle T (PymT)
transgenic mice bearing multifocal breast tumors. Transgene
expression was determined in tumor tissue 14 days after
intravenous injection of luciferase vectors. While, as in FVB mice
without tumors, AAV8-ESGLSQS vectors mediated a strong liver
bioluminescence, apparent re-direction of transgene expression to
breast cancer tissue was observed with AAV2-ESGLSQS and
AAV9-ESGLSQS vectors, being more efficient for AAV9-
ESGLSQS than in AAV2-ESGLSQS. Tumor transgene expres-
sion was not detected after injection of wild type variants (Figure 5).
These findings where confirmed by single organ lysate expression
analysis. The insertion of ESGLSQS resulted in strong gene
transduction of breast cancer tissue in all AAV serotype mutants
compared to their wild type origins (Figure 6A) and even more
efficient for AAV8-ESGLSQS (4.66105RLU/mg protein) and
AAV-9-ESGLSQS (9.76104 RLU/mg protein) than for the
‘‘original’’ AAV2-ESGLSQS (7.66104 RLU/mg protein). These
findings were supported by biodistribution analysis of vector
genome copy numbers in different tissues. The ratio of vector
genomes recovered in the tumor tissue in relation to the amount of
vector genomes recovered from the liver (Figure 6 B), respectively
from the cardiac tissue (Figure 6C) revealed favorable ratios for all
three serotypes displaying ESGLSQS compared to their respective
wild type capsids, supporting vector homing to PymT induced
breast tumor tissue. Interestingly, tumor/liver expression ratio was
most favorable with AAV2-ESGLSQS (Figure 6D), while the
tumor/heart expression ratio was slightly increased with AAV9-
ESGLSQS vectors (Figure 6E). As expected, single organ analysis
of gene expression in various tissues revealed strong but unspecific
gene transduction mediated by AAV8-ESGLSQS (Figure 6G). For
AAV9-ESGLSQS, we observed a strong de-targeting of gene
expression in liver, heart, kidney and brain compared to wild type
AAV9 (Figure 6H). However, gene transduction was not entirely
specific to tumor tissue and was also detected in the heart as was
observed for AAV2-derived vectors (Figure 6F) [32].
Taken together, our data suggest superior tumor/liver and
tumor/heart expression ratios for AAV2-ESGLSQS vectors,
indicating preferential targeting of breast tumor tissue by AAV2-
ESGLSQS. The ratio of tumor/liver expression is more favorable
for AAV2- compared to AAV9-ESGLSQS, because it seems to
confer a more pronounced de-targeting of gene expression in the
liver (Figure 6F). In turn, the expression ratio of tumor/heart is
more tumor-specific for AAV9- than for AAV2-ESGLSQS and
breast cancer gene transfer was even more efficient with AAV8-
ESGLSQS and AAV9-ESGLSQS than with AAV2-ESGLSQS.
Discussion
Targeted gene transfer has been a major area of research in
molecular medicine during the past decade. For adeno-associated
viral vectors, both the exploitation of serotypes with their unique
transduction profiles [34] as well as the introduction of targeting
peptides in the capsid, mainly of AAV2 [23,24,25,26,27,32,33],
and DNA shuffling from different serotypes [45,46,47] have been
explored for targeted gene delivery. AAV8 and AAV9 are
particularly attractive for systemic gene delivery because they
mediate strong transgene expression and have the ability to cross
endothelial barriers in some organs [5,6,7]. However, unlike for
AAV2, their natural tropism has never been modified by targeting
peptides to re-direct or confine gene transfer to certain tissues in
vivo. Here we explored whether peptides selected for tissue
targeting of AAV2 can be inserted at equivalent sites within the
capsids of AAV8 and AAV9. We found that such insertion is
compatible with capsid assembly of both serotypes and that it
indeed modifies the tropism in vivo, strongly depending on the
peptide inserted and on the serotype of the capsid it was inserted
in.
Koerber et al. recently described position 590 in the AAV8
capsid as a potential candidate site for peptide insertion and re-
targeting AAV8 vectors [40]. However, no potential insertion site
has been described for serotype 9 so far. For AAV2, such peptides
have mostly been introduced into capsid regions adjacent to N587
and R588. Comparing the capsid protein sequences of AAV2,
acid sequence of the cap gene for each corresponding serotype (single letter amino acid code) is depicted in black letters; differences compared to
the respective wild type sequence are shown in blue letters. Red indicates seven additional amino acid residues from the insertion of
oligonucleotides encoding a known peptide ligand for the re-direction of AAV serotypes. D: Model of the VP-3 capsid protein of AAV2 and
localization of R588 and E: model of the VP-3 protein of AAV8 capsid and localization of R590. The potential peptide insertion site is depicted in
yellow. Basic amino acids are depicted in red, acidic amino acids in blue. The VP-3 model of AAV2 and AAV8 was generated using Cn3D with
coordinates PDB ID: 1lp3 for AAV2 [50] and PDB ID: 2QA0 for AAV8 [37] serving as template.
doi:10.1371/journal.pone.0023101.g001
Table 1. Titers of recombinant AAV vectors.
luciferase vector
genomic titer*
[vector genomes/ml]
AAV2 wild type 9.7561010
AAV8 wild type 1.6361011
AAV9 wild type 5.3561011
AAV2-VRRPRFW 7.1761010
AAV8-VRRPRFW 2.3061011
AAV9-VRRPRFW 1.8761011
AAV2-PRSTSDP 1.2861011
AAV8-PRSTSDP 3.6361011
AAV9-PRSTSDP 6.0361011
AAV2-ESGLSQS 1.2961011
AAV8-ESGLSQS 5.3061011
AAV9-ESGLSQS 2.4661011
*vector genomes of viral stocks were determined by quantitative real-time PCR.
doi:10.1371/journal.pone.0023101.t001
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AAV8 and AAV9, we found differences among amino acids
located in subloop 4 including positions 585–595. This may
indicate that these regions are also involved in binding to serotype-
specific cellular attachment receptors of AAV8 and -9 which is
congruent with some binding characteristics that have been
described for these serotypes. AAV2 binds to heparan sulfate
proteoglycan (HSPG) via the basic amino acid residues R484,
R487, K532, R585 and R588 located near the peak of the
threefold spike. Binding to HSPG has not been reported for AAV8
and AAV9 [48]. For AAV8 and -9, the laminin receptor (lamR)
has been identified as a potential cellular receptor, but this
receptor may also serve as co-receptor for AAV2 [39]. For AAV8,
the interaction with lamR is essential for transduction of cells in
vitro and it is mediated by capsid domains near the three-fold spike
region (593–623) [39]. Recently, terminal N-linked galactose has
been described as cellular surface glycan that mediates binding of
AAV9 to its host cells [49].
Our primary hypothesis was that the insertion of peptide ligands
into the capsid sites of AAV8 and AAV9 can alter the tropism of
these AAV serotypes in vivo. This hypothesis seems to be confirmed
by our findings. Peptide insertion into these sites indeed interferes
with the transduction pattern of all three investigated serotypes. Of
note, each peptide had a distinct influence on tropism in each
serotype. Besides the binding characteristics of the inserted
peptide, changes in amino acids surrounding the insertion point
may also contribute to the modified tropism. This may apply
especially for AAV8, because in this serotype the cloning
procedure necessitated the insertion of a charged amino acid
upstream of the peptide insert.
The insertion of a control peptide (VRRPRFW) into the capsid
of AAV2, -8 and -9 resulted in transduction-deficient vectors as
expected, since this peptide had not been optimized to mediate
transduction into a certain tissue. The strong cationic nature of
residues within VRRPRFW might suggest heparin interaction of
this capsid-modified AAV, but we have shown that VRRPRFW
peptide insertion into the AAV2 capsid domain surrounding R588
results in a heparin binding deficient capsid phenotype [31].
Of note, the tropism the peptides were selected for by screening
random AAV2 peptide libraries was not per se transferable from
one serotype to another. Exceptions were the random peptide
control VRRPRFW which conferred ablation of transduction
capacity in all serotypes, and the ESGLSQS peptide that resulted
in a comparable transduction pattern both in the original
structural context AAV2 and AAV9.
Random peptide libraries displayed on AAV capsids can be
screened for capsid variants that overcome the natural AAV
transduction resistance of certain tissues in vivo [32,33]. One of the
major strengths of screening AAV libraries is that it takes into
account the unique protein context of the capsid surrounding the
targeting ligand.
Figure 2. Bioluminescence imaging of gene transduction by vectors derived from AAV2, -8 and -9 displaying peptide ligands. In vivo
bioluminescence imaging of transgene expression in FVB mice injected intravenously with rAAV-luciferase vectors harboring wild type capsid or
capsids displaying a targeting peptide selected in the structural context of AAV2. Images were taken 28 days after vector injection, when whole
animal bioluminescence intensities (BLI) reached peak values after injection of luciferase substrate. BLI ranges from 105–108 relative light units per
animal (photons/sec/cm2).
doi:10.1371/journal.pone.0023101.g002
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Figure 3. Ex vivo determination of transgene expression after systemic administration of AAV2, AAV8 and AAV9 vectors displaying
peptide ligands. Luciferase gene expression in various tissues was analyzed 28 days after intravenous injection of rAAV vectors into FVB mice.
Capsid insertion of the random VRRPRFW peptide did not result in transgene expression in any organ, while the lung-directed peptide PRSTSDP and
the breast tissue-directed peptide ESGLSQS resulted in specific changes of tissue tropism. A shows results for AAV2-, B for AAV8-, and C for AAV9-
injected animals. Values below 103 RLU/mg protein are not shown because this indicates the threshold beyond which luciferase expression data
could be reproducibly delineated from background signal. * = p,0.05; ** = p,0.01; *** = p,0.001 capsid displaying peptide versus respective wild
type control (n = 3 animals).
doi:10.1371/journal.pone.0023101.g003
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Figure 4. Biodistribution analysis of tropism-modified vectors. Vector genome copy numbers in various tissues were quantified by
quantitative real-time PCR using CMV-promoter-specific primers. Tissues were harvested 28 days after intravenous injection of capsid-modified or
wild type vectors, respectively. Recovered vector genome numbers are shown for A liver, B cardiac, and C lung tissue. (n = 3 animals per group).
doi:10.1371/journal.pone.0023101.g004
Figure 5. In vivo bioluminescence of gene expression in breast cancer tissue of PymT-transgenic mice. Luciferase vectors derived from
AAV2, -8 and -9 displaying breast cancer-directed peptides (ESGLSQS) and respective wild type capsid vectors were injected intravenously into tumor-
bearing mice (n = 3 per group). Images were taken 14 days after vector injection. BLI ranged from 105–108 relative light units per animal (photons/
sec/cm2).
doi:10.1371/journal.pone.0023101.g005
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Figure 6. Breast cancer-directed gene delivery by AAV capsids displaying ESGLSQS depends on the underlying capsid serotype. A:
Luciferase activities in PymT-induced breast cancer tissue were determined as relative light units (RLU) per mg protein 14 days after injection of AAV2,
-8 and -9 displaying breast cancer-directed peptides (ESGLSQS) or respective wild type capsid variants (n = 3). B and C: the amount of vector
genomes recovered in tumor, liver and cardiac tissue was analyzed by quantitative real-time PCR using the tissue samples as described in A (n = 3
animals per group). B: ratio of vector genome copy numbers tumor/liver (n = 3 animals per group); C: ratio of vector genome copy numbers tumor/
heart. D and E: ratios of gene transduction using AAV vectors of serotypes 2, 8 and 9 with insertion of the ESGLSQS peptide and respective wild type
variants. Values were calculated as D: tumor/liver expression ratios or E: tumor/heart expression ratios, respectively. F, G and H: Luciferase activities
in various tissues were detected as relative light units (RLU) per mg protein for AAV-2 (F) for AAV-8 (G) and AAV-9 (H) displaying breast cancer-
directed peptides (ESGLSQS) or respective AAV wild type capsid variants (n = 3 animals per group).
doi:10.1371/journal.pone.0023101.g006
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Yet, despite the fact that the complex capsid structure of AAV8
and AAV9 may be different from AAV2 in the domain we inserted
the ligands in, there is some evidence that the use of alternative
parental serotype capsids may also provide advantages. In fact,
gene delivery to breast tumor tissue by our novel vectors AAV8-
ESGLSQS and AAV9-ESGLSQS is superior compared to the
AAV2 capsid that has been selected by AAV2 library screening.
The comparable in vivo transduction profile of AAV9 and
AAV2 displaying ESGLSQS suggests that both vector variants
may use the same molecular transduction mechanism presum-
ably by binding to the same receptors or class of receptors.
Another pertinent point is that peptide insertion into the
threefold spike domain of AAV serotypes 8 and 9 could further
facilitate the development of vectors able to escape host-derived
neutralizing antibodies as it has been shown for AAV2 vectors
[36]. This is especially relevant in view of the fact that there is
little prevalence of neutralizing antibodies even to wild type
AAV8 and -9 in the general population [11].
AAV2 vectors displaying PRSTSDP were selected for optimized
lung transduction. This peptide expanded instead of restricted
AAV2 tropism to the lung, because the endogenous AAV2 tropism
does not allow for lung transduction and, in turn, AAV2-
PRSTSDP vector tropism included but was not limited to the
lung [32]. In contrast to the transduction of tumor tissue with
vectors displaying the ESGLSQS peptide, the best transduction of
lung tissue was observed with the PRSTSDP peptide when it was
displayed in AAV2. Transfer of the peptide to the two other
serotypes did not result in equally efficient gene delivery to this
tissue. This suggests that at least for some peptides the parental
serotype that has been used for peptide library screening is crucial
for the transduction of the target tissue.
Taken together, we observed both improved target tissue
transduction with peptides in AAV8 and AAV9 as opposed to
AAV2 on the one hand and optimal transduction only in the
original AAV2 context on the other hand. Therefore, we suggest
that random peptide libraries displayed on AAV8 and AAV9
should be established and screened in vivo to select AAV with
optimal specificity and efficiency for the target tissue.
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